In the study of metastatic carcinomaof an unknown primary site, Gurel et al. found that the vast majorityof metastatic prostate adenocarcinomas (98.6%) retained NKX3.1 expression,while only 1 of 383 cases of nonprostatic tumors expressed NKX3.1.38 Another similar work was provided by Huang etal., demonstrating that PSMA and NKX3.1 are more sensitive markersthan PSA for bone metastasis of PCa, following decalcification.39 Based on the available data, we developed asimilar phenotype by suppressing the expression of NKX3.1 at a certainlevel. The gene discussed is FOLH1; the disease is posterior cortical atrophy.